Antiviral therapy for chronic hepatitis C in 2014

Manogna Nookathota, Sandeep Mukherjee

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.

Original languageEnglish
Pages (from-to)499-505
Number of pages7
JournalExpert Review of Clinical Pharmacology
Volume7
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Chronic Hepatitis C
Antiviral Agents
Interferons
Genotype
Therapeutics
Peer Review
Hepatitis C
Disease Management
Fibrosis
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Medicine(all)

Cite this

Antiviral therapy for chronic hepatitis C in 2014. / Nookathota, Manogna; Mukherjee, Sandeep.

In: Expert Review of Clinical Pharmacology, Vol. 7, No. 4, 2014, p. 499-505.

Research output: Contribution to journalReview article

@article{98cfe540cafd49e2bdb1af222de14b80,
title = "Antiviral therapy for chronic hepatitis C in 2014",
abstract = "An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.",
author = "Manogna Nookathota and Sandeep Mukherjee",
year = "2014",
doi = "10.1586/17512433.2014.915737",
language = "English",
volume = "7",
pages = "499--505",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Antiviral therapy for chronic hepatitis C in 2014

AU - Nookathota, Manogna

AU - Mukherjee, Sandeep

PY - 2014

Y1 - 2014

N2 - An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.

AB - An all-oral therapy for treating hepatitis C (HCV) is now available for the most common genotypes although interferon-based therapy is still recommended for interferon-eligible patients with HCV genotype 1. For most patients, a prior history of treatment or presence of cirrhosis does not appear to significantly impact eradication rates with direct acting antivirals (DAA). The promising results from the numerous clinical trials of DAA's for HCV together with their tolerability represent a tremendous advance in our management of this disease, particularly as treatment is often well-tolerated, associated with few side effects and significantly shortened in duration. We will review several of the peer-reviewed landmark studies of DAA's for the treatment HCV and conclude with an expert commentary and five year view.

UR - http://www.scopus.com/inward/record.url?scp=84903186698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903186698&partnerID=8YFLogxK

U2 - 10.1586/17512433.2014.915737

DO - 10.1586/17512433.2014.915737

M3 - Review article

C2 - 24939471

AN - SCOPUS:84903186698

VL - 7

SP - 499

EP - 505

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -